Baxter Pharmaceutical Solutions, LLC – FDA 483, Nov 10, 2021
An FDA inspection of Baxter Pharmaceuticals Solutions, LLC in Bloomington, IN, revealed significant deficiencies in quality control and facility maintenance. Observations included a failure to thoroughly review unexplained discrepancies in product rejection rates, persistent insect infestation in classified manufacturing areas despite multiple corrective actions, and a lack of adequate authority for the Quality Control unit to fully investigate errors due to restricted access to critical production areas. These issues suggest a systemic breakdown in quality oversight and environmental control.
ID · e58a0478-5a31-4b0c-bf8f-43a2a2cd7673
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.